ELV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Elevance Health Inc (ELV) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite mixed analyst ratings and regulatory scrutiny, the company's strong net income and EPS growth, coupled with significant congressional purchases, indicate confidence in the stock's long-term potential.
The technical indicators for ELV are neutral. The MACD is below 0 but negatively contracting, RSI is neutral at 47.622, and moving averages are converging. The stock is trading near its pivot point of 336.629, with support at 326.109 and resistance at 347.15. No clear bullish or bearish signals are present.
Congress members made 4 purchase transactions in the last 90 days, indicating strong confidence in the stock.
Significant YoY growth in net income (+30.86%) and EPS (+36.46%) in Q4
Analysts like JPMorgan and UBS maintain Buy/Overweight ratings with price targets above the current price.
Regulatory scrutiny from the House Judiciary Committee regarding potential fraud in ACA enrollees.
Hedge funds are selling, with a 135.25% increase in selling activity over the last quarter.
Analysts like RBC Capital downgraded the stock to Sector Perform, citing softer 2026 guidance and margin outlook.
In Q4 2025, Elevance Health reported a revenue drop of -9.50% YoY to $41.13B. However, net income increased by 30.86% YoY to $547M, and EPS rose by 36.46% YoY to 2.47. This indicates strong profitability despite revenue challenges.
Analyst ratings are mixed. RBC Capital downgraded the stock, citing softer guidance, while JPMorgan, UBS, and others maintain Buy/Overweight ratings with price targets ranging from $390 to $409. The consensus reflects cautious optimism, with some concerns over future margins and growth.
